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This paper shows why high throughput screeningprogrammes have
become a fast growing area in which laboratory automation is
playing a critical role. The unique philosophical and technical
problems associated with high throughput screening are examined,
and the paper explains how a team-based approach to solving these
automation problems has become crucial in the successful
implementation of these tasks.
Introduction
High throughput screening, perhaps more than any other
laboratory automation task, illustrates the need for a
diverse set of skills that can be brought together to solve
a critical need in the pharmaceutical industry, namely
the rapid and efficient discovery of new pharmacophores
against a diverse set of disease targets. The resources
needed for the development of an assay suitable for high
throughput screening can include the scientific disciplines
of molecular biology, biochemistry, analytical chemistry,
computer database technology, robotics and automation,
chemistry, industrial engineering, instrument develop-
ment, statistical process control, project planning and
electronics. In order to draw together the diverse set of
talents that will be drawn on to get the screen into
automated operation, managers need team-building and
leadership qualities to achieve success. These leadership
skills are needed to get commitment and buy-in, not only
from the people implementing the screen on a day-to-day
basis, but also those in the management of the research
organization. This is necessary in order to sell the
significant commitment in investment that modern
state-of-the-art high throughput screening demands.
Also important is the involvement of the scientific staff
and the management of the therapeutic areas for which
the high throughput screen has been established, so that
the lead compounds discovered during the screening
process are evaluated properly in the follow-up assays for
that disease, and become a source of lead chemotypes for
synthetic chemical follow-up and target drug development.
The last two to three years have seen a massive increased
interest in high throughput screening as a mechanism for
new drug discovery. The reasons for this focus have come
from the increased competitive pressures in the pharma-
ceutical market-place and show no signs of abating in
the near future. The main competitive forces that are
generating these pressures are from the changing health-
care environment on costs and the demand for novel and
effective therapies for chronic diseases. Even without
government pressures in the USA for health care reform
(cost containment), the market environment has changed
considerably with the cost-containment pressures from
Health Management Organizations (HMOs) and insur-
ance companies on the pharmaceutical industry. Despite
the high cost-benefit ratio that is realized from treating
medical conditions with drugs, and the fact that they
constitute only a small percentage of total health care
costs, there is still considerable pressure for reducing the
patient cost of pharmaceuticals. In addition, the selection
of preferred drugs by HMOs, hospitals and government
organizations for particular disease groups and the
establishment of preferred formularies, has led to internal
competitive pressures within the industry to be the first
with novel therapies. This is to ensure that these products
are on the preferred lists ahead of the competition.
The result of these developments has been the drive to
produce new drug candidates from discovery research at
an ever-increasing pace, with little or no prospect for
massive increases in drug discovery resources to the
research arm of the pharmaceutical industry.
Although high throughput screening has become a major
factor in drug discovery for a balanced programme of
drug discovery, a combination of approaches will yield
the best results in the development of lead compounds.
These approaches will include a combination of rational
drug design based on knowledge of the three-dimensional
structure of the target and active sites, traditional
medicinal chemistry approaches based on chemical
synthesis around known therapeutic agents or the best
intuition as to potentially active compounds, and random
high throughput screening.
However, the one advantage that high throughput
screening in recent years has been able to offer is a
relatively low cost to entry for the discovery of low
molecular weight pharmacologic agents to many stellar
biotechnology companies and it has received increased
emphasis by the larger pharmaceutical houses as a
mechanism for generating new drug candidates faster.
The new biotechnology companies that have access to
new targets through recombinant technologies have found
that large molecular weight biologicals have a special set
ofdevelopment, drug delivery and approval problems that
have not kept up with the promise of a few years ago.
Small molecules are also a better source ofdrug candidates
than expensive rational drug design programmes.
The promise that high throughput screening (HTS) offers
pharmaceutical companies of any size is the potential to
generate lead candidates quickly, and to potentially
discover compounds with radically different pharmaco-
phores than can be predicted on the basis of pre-existing
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drugs or rational design criteria. These factors are now
leading to the shortening of the discovery cycle and a
movement away from ’metoo’ compounds, but this
pressure has resulted in new obstacles for high throughput
screening. These are the numbers, chemical diversity of
compound libraries, cost and time (how many compounds
should be screened to discover with the highest probability
desired, all potentially novel chemotypes, how diverse does
a company’s compound collection have to be to cover all
possible pharmacophores for a given target; how fast can
the library be screened; can this be done at a low enough
cost to be economically feasible?). These questions are at
the heart of state-of-the-art high throughput screening
programmes, and have serious implications about how a
successful HTS programme can be implemented and have
a significant impact on the design of automated HTS
systems.
HTS today
Because of the increased competitive environment, the
pressure to increase the sample throughput continues. In
the late 1980s a general industry average for high
throughput was about 75,000 compounds/screen per year
to 113 months. A screen could run from a year to two years
before being replaced by a new screen. Automation was
minimal at best, simple robotic one arm systems. Com-
pounds could be fed into the system within the screening
department, and automated distribution systems were
relatively unknown. Automation could be implemented
either on a turn-key basis from a vendor (often with large
system delivery times), or the system protocols could easily
be established relatively slowly in house. Natural product
screening was still an equal partner with synthetic
chemical screening.
This scenario rapidly began to change in the early 1990s.
The realization that a company’s compound library was
a potentially valuable screening source quickly led to the
need to increase the pace at which compounds could be
delivered to the screens existing in place at that time. This
was coupled with the introduction of intelligent work-
stations, not only in the HTS laboratory, but in the
research laboratories that simplified the liquid handling
procedures needed for most biochemical and biological
assays then used for high throughput screening. This
resulted in more synthetic compound screening growing
on an ad hoc basis, both in therapeutic area laboratories
and HTS labs. Most pharmaceutical houses with com-
pound libraries in the range of 75000 to 150000
compounds soon realized that some of the institutional
barriers to synthetic compound screening had dropped,
and that practical compound deck screening had arrived.
The infrastructure necessary to handle this process
contributed to the move towards centralization of HTS
departments. The realization that the discovery of a lead
chemotype from a synthetic deck compound of known
structure short-circuited the isolation/structure identifi-
cation process from natural product leads has resulted in
a vigorous debate about the contribution of natural
product screening to drug discovery. This, in turn, has
led to efforts to re-engineer the natural product drug
discovery process to make it more efficient in the
identification both of lead drug candidates from natural
sources, and the identification of novel chemotypes that
can be fed into the iterative cycle of structure-activity
optimization. High throughput screening ofboth synthetic
decks, and decks of commercially available natural
product extracts, has become attractive to small bio-
technology companies without the need to develop the
costly, complex infrastructure necessary for fermentation
and isolation of natural products.
The race to screen compound decks has begun in earnest
and there are many more players than there were a decade
ago.
What might have been 150000 compounds in two years
today approaches that same number in a short number
of months. Without too much extrapolation into fantasy
land, this period could easily become weeks or days. This
compression of the cycle time for HTS has led to serious
strains in the infrastructure supporting HTS, nowhere else
more so than in the people developing, implementing and
running the screens. This is where team building and
leadership are so important to the successful imple-
mentation of the automation necessary to run samples
through HTS screens at this rate.
As mentioned above, the reasons for the increased pressure
to screen samples faster come from four forces that show
no signs of abating in the near future and require a major
shift in management’s approach to both the personnel
and capital infrastructure necessary for successful high
throughput screening. These pressures come from health
care reform; the human genome project (HUGO); the
development of combinatorial chemistry; and the instru-
mental and technology advances generated by the micro-
electronics and miniaturization revolution. As these
revolutionary developments continue to affect the phar-
maceutical industry, management will need to turn more
and more to finding ways to cope with the impact of these
technologies on the work force. Automation, particularly,
can be perceived as a threat to people’s way of doing
things, and the introduction ofautomation in an inappro-
priate way can lead to such resistance that the goals that
are expected ofautomated systems are not achieved. One
way to avoid this pitfall in implementing automation
within HTS is to build in the commitment to automation
as part of the team-building effort needed to achieve the
goals of an HTS group.
The capital and skilled manpower requirements for HTS
have led to the trend in most large pharmaceutical
companies to develop and establish centralized HTS
efforts. This minimizes the duplication of the capital
investment in hardware, facilities and people. The last two
Society for Biochemical Screening meetings have recog-
nized that there is a growing specialization in skills for
HTS, and that these skills are in short supply. The central-
ization of the HTS group does have dangers that have to
be addressed by management. These include the need to
get early interaction between the HTS group and
therapeutic area scientists early to develop screens with
assay protocols most suited to unattended, automated
HTS; the development of recognition systems for those
running the screens; and follow-up support and the
education of upper management in the resource commit-
ment for HTS. This not only includes the capital
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infrastructure necessary to screen, but the support for
supply reagents to the screen, rapid follow up of leads
biologically and sufficient chemistry support to develop
lead chemotypes into drug candidates.
Infrastructure commitment not only means the capital
necessary for the automated systems for screening, but
provision of automated systems for the rapid follow-up of
lead chemotypes, automated chemistry efforts for directed
SAR synthesis, interaction with compound centers for
automated storage, retrieval and dissolution systems, as
well as the effective company-wide management of the
data generated quickly and in large amounts from a good
HTS effort. Management of HTS groups have to build
these resources into a team that can respond quickly to
both the results of a discovery effort, but also one that
can quickly adapt to changing priorities for therapeutic
area targets. Again it is clear that people issues, and getting
them to function as a team leads to successful imple-
mentation of an HTS programme.
In addition, technology is driving change. Over the last
few years, those assays that have the highest throughput
and are easiest to develop, validate and implement are
those that require the least actions on the part of
automated systems. The best examples of these are the
’Mix and measure’ type of assay. These can range from
microbially based assays (both traditional antimicrobial
assays, or assays based on engineering target genes into
microbes with reporter systems), enzymic assays, or
homogeneous assays (such as fluorescence polarization
and the DELFIA time resolved fluorescence assays).
Sportsman (Terrapin Technologies) has reported through-
put ofa microplate every three minutes using fluorescence
polarization technology. This can result in over 400
microplates/day throughput with a sample capability of
over 30000 samples throughput per day. Assays that
require complex separation steps (for example, radio-
ligand binding assays with filtration steps) are assays that,
while suitable for more modest throughput, are problematic
with unattended automated systems.
The trend towards the HTS as a service-oriented group
to the different therapeutic areas also leads to problems
in recognizing the real scientific contribution of the team
that takes a new screen from cradle to grave, where the
output is lead pharmacophores that often are altered
beyond recognition in the drug candidate development
process. The need for management and peers outside the
HTS group to recognize these efforts as a real and tangible
contribution to the drug discovery is often a real barrier
to getting commitment of the HTS team from the start.
At Bristol-Myers Squibb, the involvement ofthe screening
and therapeutic area scientists at the early stages of goal
setting for implementation of a high throughput screen is
considered vital to the successful achievement ofthat goal.
This is illustrated by the company’s experience with a
rather cumbersome to implement enzyme screen that had
become high priority in order to select a back-up
candidate for a cardiovascular programme. It took the
involvement of three people from the enzyme-based
screening group and two people from the robotics group
working as a team to develop novel product separation
methodology that made the assay a viable one for HTS.
It also took the involvement of therapeutic area scientists
providing reagents and follow-up assays, and the commit-
ment of one, and sometimes two, people from the
compound distribution group to screen the entire com-
pound deck within three to four months. A number of
novel chemotypes emerged from this effort and it was
successful because of the focus of the people involved
working through many obstacles to implement the
automation, resulting in the required throughput.
However, with the drive to increase throughput, the scope
ofautomation becomes so great that even greater planning
for the team’s effort will start at earlier and earlier stages
in the design of the assay for automation. This starts
further and further back into the conceptualization phase
of the target selection and assay design, and even greater
team effort is required from both the therapeutic area
scientists and earlier involvement of the various areas of
expertise within HTS.
It is important to recognize that, for successful application
of automation, people skills are vital, and the technology
needs are secondary. A manager with vision to lead the
team consisting of individuals with a diverse set of skills
is needed to inspire the team to success, and mould these
individual skills towards a team goal rather than
individual objectives. The leader also needs to recognize
that the team does not function in a vacuum and has to
share the vision of the goals, not only with the team, but
with higher management who also have to commit
resources in manpower and capital to the project.
In order to implement automation successfully, one must
have a defined goal in mind for the outcome ofthe project.
The procedure then has been broken down into its unit
operations before automation is contemplated. This is the
’white board’ stage of laboratory automation. If you
outline the process and there is a step that you cannot do
robotically, alarm bells should be sounding loud. This
white board model also allows the critical team skills that
the project needs to be pinpointed at the start, rather
than half way through. At this stage, the team should
meet and walk through the project, and responsibility
should be accepted for the various steps. This may include
biochemists to fine tune the chemistry or biology; the
engineering support group to start to build all those little
(or not so little) widgets that are needed; the data analysis
people; and the automation group. At this time, the leader
of the project should be selected and should begin to
co-ordinate the process and build a project planning time
line. Periodically, as the project progresses, assessments of
progress and trouble-shooting sessions are necessary, until
the preliminary implementation of the project is ready.
Once the system is up and running for the first time, the
same team members are needed for their feedback in
validating the system, and also the follow-up during the
initial running of the high throughput screen. Upper
management should be kept informed of the progress of
the project.
Following these guidelines will lead an automation project
to success.
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Conclusion
No matter how much the people in a high throughput
screening laboratory commit themselves to increased
throughput by the use of appropriate automation, the
pressure to develop the next generation of automation is
always around the corner. The same competitive pressures
that the pharmaceutical industry faces today will be
present for the foreseeable future. This will be the result
of the need for continued reduction in lead time to drug
discovery, the continued impact of HUGO technology,
the throughput ’forcing’ by combinatorial and high speed
parallel combinatorial synthetic chemistry and the
renewed emphasis on improving the efficiency of natural
products screening and the impact of new technologies.
These include the recent proliferation of automation
integrators and vendors (which will lead to an increase
in the ease of use of automation, as each vendor tries to
make the systems more modular, integrable and user-
friendly). Ifwe assume an analogous situation in automa-
tion and robotics to that which existed in the early
days ofanalytical instrumentation, then the next few years
should bring a low cost to automation and a more
off-the-shelf approach to modular robotics systems. This
approach to instrumentation will also impact on combi-
natorial chemistry. The ease of set up of combinatorial
chemistry programmes using the off-the-shelf and easy-
to-use instrumentation will continue the spiral ofincreased
sample load into HTS systems. It will not be uncommon
for compound collections to become to 2 million in size.
In addition, fall out of instrumentation from the HUGO
project will affect the assay methodologies used for screen
development. Microminiaturization of assays, including
silicon-based chip sensors, micro-fabricated liquid-handling
systems on a chip and modern sensor technology from the
US defence programme will also impact the capability to
screen large numbers of compounds cheaply. We are
starting to see some of this technology already. The
development ofthe 384-well microplate, whole plate CCD
fluorescence readers, and newer 96-well pipetting devices
are already in the market-place.
Also the impact of highly efficient, cheap computing
power is making itself felt in harnessing the data torrent
that is pouring out of HTS laboratories. Modern multi-
tasking operating systems and object oriented program-
ming techniques also promise to assist with the data flood.
Artificial intelligence, neural networks and virtual reality
techniques will all have some impact, the directions and
applications of which we presently cannot conceive.
These developments will not let high throughput screening
automation groups rest at today’s level of throughput.
The stage will be set for the conversion to full-scale
production technology HTS for drug discovery. The
company that seizes on this concept and this opportunity
will be one of the few that will have the luxury
of overflowing drug pipelines into the next century.
Ultimately, however, it will not be the technology that
will deliver this wealth, but the people behind the
technology and their willingness to embrace change,
function as a team to harness it, and to be the recipients
of the rewards of that foresight.
In summary, people in HTS laboratories, and especially
their management, face exciting challenges as we move
into the next century. The industrial power inherent in
the HTS philosophy promises to produce an abundance
of new therapeutic agents, but can only be achieved by
the total involvement of the HTS team in setting up and
applying the technology necessary for any pharmaceutical
company to be competitive in the market-place of today
and the future.
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